153 related articles for article (PubMed ID: 37648295)
21. Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study.
Sung KW; Son MH; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ; Lee SK; Choi YS; Lim DH; Kim JS; Kim DW
Bone Marrow Transplant; 2013 Jan; 48(1):68-73. PubMed ID: 22635247
[TBL] [Abstract][Full Text] [Related]
22. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study.
Kletzel M; Katzenstein HM; Haut PR; Yu AL; Morgan E; Reynolds M; Geissler G; Marymount MH; Liu D; Kalapurakal JA; Shore RM; Bardo DM; Schmoldt J; Rademaker AW; Cohn SL
J Clin Oncol; 2002 May; 20(9):2284-92. PubMed ID: 11980999
[TBL] [Abstract][Full Text] [Related]
23. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
[TBL] [Abstract][Full Text] [Related]
24. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
[TBL] [Abstract][Full Text] [Related]
25. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
[TBL] [Abstract][Full Text] [Related]
26. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results.
Matthay KK; O'Leary MC; Ramsay NK; Villablanca J; Reynolds CP; Atkinson JB; Haase GM; Stram DO; Seeger RC
Eur J Cancer; 1995; 31A(4):572-5. PubMed ID: 7576971
[TBL] [Abstract][Full Text] [Related]
27. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
Berthold F; Boos J; Burdach S; Erttmann R; Henze G; Hermann J; Klingebiel T; Kremens B; Schilling FH; Schrappe M; Simon T; Hero B
Lancet Oncol; 2005 Sep; 6(9):649-58. PubMed ID: 16129365
[TBL] [Abstract][Full Text] [Related]
28.
Giardino S; Piccardo A; Conte M; Puntoni M; Bertelli E; Sorrentino S; Montera M; Risso M; Caviglia I; Altrinetti V; Lanino E; Faraci M; Garaventa A
Pediatr Blood Cancer; 2021 Feb; 68(2):e28775. PubMed ID: 33099289
[TBL] [Abstract][Full Text] [Related]
29. Stem cell transplantation for neuroblastoma.
Fish JD; Grupp SA
Bone Marrow Transplant; 2008 Jan; 41(2):159-65. PubMed ID: 18037943
[TBL] [Abstract][Full Text] [Related]
30. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
Matthay KK; Villablanca JG; Seeger RC; Stram DO; Harris RE; Ramsay NK; Swift P; Shimada H; Black CT; Brodeur GM; Gerbing RB; Reynolds CP
N Engl J Med; 1999 Oct; 341(16):1165-73. PubMed ID: 10519894
[TBL] [Abstract][Full Text] [Related]
31. Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Tushabe DA; Berthold F
Cochrane Database Syst Rev; 2015 Jan; 1():CD010685. PubMed ID: 25634649
[TBL] [Abstract][Full Text] [Related]
32. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
[TBL] [Abstract][Full Text] [Related]
33. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.
Berthold F; Faldum A; Ernst A; Boos J; Dilloo D; Eggert A; Fischer M; Frühwald M; Henze G; Klingebiel T; Kratz C; Kremens B; Krug B; Leuschner I; Schmidt M; Schmidt R; Schumacher-Kuckelkorn R; von Schweinitz D; Schilling FH; Theissen J; Volland R; Hero B; Simon T
Ann Oncol; 2020 Mar; 31(3):422-429. PubMed ID: 32067684
[TBL] [Abstract][Full Text] [Related]
34. Neuroblastoma: Essential genetic pathways and current therapeutic options.
Salemi F; Alam W; Hassani MS; Hashemi SZ; Jafari AA; Mirmoeeni SMS; Arbab M; Mortazavizadeh SMR; Khan H
Eur J Pharmacol; 2022 Jul; 926():175030. PubMed ID: 35605657
[TBL] [Abstract][Full Text] [Related]
35. Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience.
Zaky W; Dhall G; Ji L; Haley K; Allen J; Atlas M; Bertolone S; Cornelius A; Gardner S; Patel R; Pradhan K; Shen V; Thompson S; Torkildson J; Sposto R; Finlay JL
Pediatr Blood Cancer; 2014 Jan; 61(1):95-101. PubMed ID: 23934933
[TBL] [Abstract][Full Text] [Related]
36. Fifteen years' review of advanced childhood neuroblastoma from a single institution in Hong Kong.
Leung CK
Chin Med J (Engl); 1998 May; 111(5):466-9. PubMed ID: 10374361
[TBL] [Abstract][Full Text] [Related]
37. Molecularly guided therapy of neuroblastoma: a review of different approaches.
Tonini GP; Pistoia V
Curr Pharm Des; 2006; 12(18):2303-17. PubMed ID: 16787256
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.
Berthold F; Ernst A; Hero B; Klingebiel T; Kremens B; Schilling FH; Simon T
Br J Cancer; 2018 Aug; 119(3):282-290. PubMed ID: 29991700
[TBL] [Abstract][Full Text] [Related]
39. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.
Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Klingebiel T; Berthold F
BMC Cancer; 2011 Jan; 11():21. PubMed ID: 21244693
[TBL] [Abstract][Full Text] [Related]
40. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.
Granger MM; Naranjo A; Bagatell R; DuBois SG; McCune JS; Tenney SC; Weiss BD; Mosse YP; Asgharzadeh S; Grupp SA; Hogarty MD; Gastier-Foster JM; Mills D; Shulkin BL; Parisi MT; London WB; Han-Chang J; Panoff J; von Allmen D; Jarzembowski JA; Park JR; Yanik GA
Transplant Cell Ther; 2021 Jun; 27(6):490.e1-490.e8. PubMed ID: 33823167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]